IOL CHEMICALS AND PHARMACEUTICALS LIMITED

10th August 2026
IOLCP/CGC/2026

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051
Security Symbol: IOLCP

BSE Limited,
Pheroze Jeejeebhoy Tower,
Dalal Street, Mumbai- 400 001
Security Code: 524164

Subject: Press Release – Financial Results for the quarter ended 30th June 2026

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release dated 10th August 2026 with respect to the financial results of the Company for the quarter ended 30th June 2026.

You are requested to take the same on record.

Thanking You,

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

ABHAY RAJ SINGH

Digitally signed by ABHAY RAJ SINGH
DN: c=IN, st=Punjab, 2.5.4.20=9b5fb24ffd5e1618227129f5800bba452021e7d448ced7f36ecace3e8e60188c, postalCode=142022, street=So Shri Brij Raj Singh Flat No O06 Royal View Homes Omaxe Residency Pakhowal Road Thakarwal, pseudonym=a48ff9e8136649fba2f091e9f81ad5a6, title=4478, serialNumber=4eddb9d8fa2badd1aec2177edceb9bcb5686d0add922a187c263226373e6063e, o=Personal, cn=ABHAY RAJ SINGH
Date: 2026.08.10 17:46:34 +05'30'

Abhay Raj Singh
Sr. Vice President & Company Secretary

IOL Chemicals And Pharmaceuticals Limited

IOL Chemicals and Pharmaceuticals Limited Reports Q1 FY27 Results

Record Quarterly Performance with Highest-Ever Revenue

Ludhiana, 10th August 2026: IOL Chemicals & Pharmaceuticals Ltd., one of the leading Active Pharmaceutical Ingredient (API) manufacturers, announced its Unaudited Financial Results for the quarter ended 30th June 2026.

Q1 FY27 Financial Performance Snapshot (Y-o-Y) *(Standalone)*

Revenue from Operations	EBITDA	PAT
₹756.3 Cr	₹ 111.7 Cr	₹ 64.5 Cr
▲ *37.1%*	▲ *60.7%*	▲ *89.9%*

Key Standalone Financial Highlights

Particulars (₹ Cr)	Q1 FY27	Q1 FY26	Y-o-Y	Q4 FY26	Q-o-Q	FY26
Revenue from Operations	756.3	551.7	*37.1%*	619.5	22.1%	2319.1
EBITDA	111.7	69.5	*60.7%*	94.3	18.5%	290.4
EBITDA Margin (%)	14.6%	12.4%		15.2%		12.4%
PAT	64.5	34.0	*89.9%*	53.2	21.2%	137.7
PAT Margin (%)	8.4%	6.1%		8.6%		5.9%

Segment Highlights

(In ₹ Cr)



Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said,

"We have commenced FY27 with a record quarterly performance, delivering our highest-ever revenue. This performance is particularly encouraging given the backdrop of geopolitical uncertainties, supply chain disruptions, and inflationary pressures across select raw materials. Healthy growth and year-on-year margin expansion were supported by improved capacity utilisation, favourable product mix and operational efficiencies.

Our Pharmaceuticals business remained a key growth driver, with revenue increasing 43% YoY and EBIT growing 72% YoY. Non-Ibuprofen products contributed 43% of Pharma revenue in Q1 FY27, up from 36% a year ago, led by healthy demand across Paracetamol, Pantoprazole, Metformin, Fenofibrate and other APIs. Paracetamol capacity utilisation also improved to 65% from 60% in the previous quarter.

The Chemicals business delivered 29% YoY revenue growth and 193% YoY EBIT growth, supported by improved operational efficiencies, disciplined and efficient raw-material procurement, better realisations and higher exports.

Our overall export performance continued to strengthen, with exports contributing 28.5% of revenue compared with 24.4% in Q1 FY26, reflecting growing traction across international markets. We are also pleased to share that our Clopidogrel API product has received NMPA approval in China, in addition to our valid CEP, further expanding our access to the Chinese pharmaceutical market.

Going forward, we remain focused on scaling our portfolio, improving product mix, enhancing capacity utilization, and expanding our presence across value-added APIs and specialty chemicals. We remain confident of building on this momentum and delivering sustainable long-term growth."

About IOL Chemicals and Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world's largest producer of Ibuprofen with a 30% global market share, among the largest global producers of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP's API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience.

Contact Details

IOL Chemicals & Pharmaceuticals Ltd.	Investor Relations: MUFG Intime India Pvt. Ltd.
CIN: L24116PB1986PLC007030	Ms. Prachi Ambre prachi.ambre@in.mpms.mufg.com Mr. Irfan Raeen irfan.raeen@in.mpms.mufg.com
Mr. Abhay Raj Singh Sr. VP & Company Secretary investor@iolcp.com	Meeting Request Link Website: https://in.mpms.mufg.com/

Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.